Q-omics provides the consensus-scored STK19B profile across patient tissues and cancer cell-line models. STK19B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, STK19B is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, STK19B RNA expression shows 8,119 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LUAD, KIRC, and KIRP as cancer lineages where STK19B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STK19B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STK19B survival associations across molecular data types. STK19B RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STK19B RNA expression–survival associations across cancer types. High STK19B expression shows unfavorable associations in LUAD, STAD, KIRC and CHOL, but favorable associations in KIRP and BLCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for STK19B RNA expression.
This table summarizes STK19B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for STK19B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STK19B shows lower tumor expression in KICH and higher tumor expression in KIRC, LIHC, BRCA, CHOL and LUSC. The KIRC box plot shows higher STK19B RNA expression in tumor versus normal tissue (log2 FC = +0.732, t-test p < 0.001).
This table shows molecular features associated with STK19B in patient tissues and cancer cell lines. In patient samples, STK19B shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
